CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis.
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在 CF 中所见的多合并症背景下,CAR-T 细胞治疗桥接 HSCT 可能是儿童难治性 ALL 的一种有效策略。
引言:急性淋巴细胞白血病(ALL)与囊性纤维化(CF)同时发生十分罕见。本文报告一例患有CF和难治性B细胞前体(BCP)ALL的儿童患者,接受CAR-T 细胞联合异基因造血干细胞移植(HSCT)治疗。 病例描述:自体CD19靶向CAR-T 细胞使患者达到分子学缓解,并避免了化疗相关毒性。由于未达到B细胞再生障碍,患者随后在全身照射(TBI)预处理方案后接受HSCT。移植后病程并发肝静脉闭塞性疾病、癫痫持续状态及肺部侵袭性真菌感染;尽管积极治疗,影像学表现仍逐渐恶化。HSCT后5个月,患者成功接受左肺上叶切除术。移植后13个月,患者疾病完全缓解,肺功能正常。 结论:对于合并多种疾病的儿童难治性ALL患者(如CF患者),CAR-T 作为桥接HSCT的治疗策略可能有效。
INTRODUCTION: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by CF and refractory B-cell precursor (BCP) ALL, who was treated with combined chimeric antigen receptor T-cells (CAR-T) and allogeneic haematopoietic stem cell transplantation (HSCT). CASE DESCRIPTION: Autologous-CD19 targeting CAR-T allowed to achieve molecular remission and spare chemo-related toxicity. As B-cell aplasia was not achieved, the patient underwent HSCT after total body irradiation (TBI)-based conditioning. The course after HSCT was complicated by veno-occlusive disease, status epileptic and pulmonary invasive fungal infection which showed progressive radiological worsening despite aggressive treatment. Five months after HSCT a left upper lobe lobectomy was successfully performed. Thirteen months after HSCT the patient is in complete disease remission with normal lung function. CONCLUSIONS: CAR-T cell therapy bridge-to-HSCT may be an effective approach in paediatric refractory ALL in the context of multiple comorbidities as observed in CF.
MEMBER ACCOUNT
登录成功会直接打开下一页。